Australia markets closed
  • ALL ORDS

    6,678.70
    -81.90 (-1.21%)
     
  • ASX 200

    6,474.20
    -80.80 (-1.23%)
     
  • AUD/USD

    0.6406
    -0.0098 (-1.51%)
     
  • OIL

    79.74
    -1.49 (-1.83%)
     
  • GOLD

    1,668.30
    -0.30 (-0.02%)
     
  • BTC-AUD

    30,221.27
    -536.55 (-1.74%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • AUD/EUR

    0.6531
    -0.0085 (-1.28%)
     
  • AUD/NZD

    1.1439
    +0.0099 (+0.88%)
     
  • NZX 50

    11,065.71
    -134.33 (-1.20%)
     
  • NASDAQ

    10,971.22
    -193.56 (-1.73%)
     
  • FTSE

    6,893.81
    +12.22 (+0.18%)
     
  • Dow Jones

    28,725.51
    -500.10 (-1.71%)
     
  • DAX

    12,114.36
    +138.81 (+1.16%)
     
  • Hang Seng

    17,222.83
    +56.96 (+0.33%)
     
  • NIKKEI 225

    25,937.21
    -484.84 (-1.83%)
     

Catalent's New Acquisition will Expand High-Potent Capabilities, Oral Manufacturing Capacity: Report

·1-min read
  • Catalent Inc (NYSE: CTLTagreed to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization, for $475 million from Mayne Pharma Group Limited.

  • Upon completion, the acquisition will strengthen Catalent's integrated oral solid formulation development, manufacturing, and packaging capabilities.

  • The deal will also expand Catalent's capacity to handle highly potent compounds.

  • Metrics Contract operates a 333,000-square-foot facility in Greenville, North Carolina. It includes 16 manufacturing suites, with 11 designed to handle highly potent compounds and two packaging lines.

  • The facility's estimated annual production capacity exceeds one billion oral solid dose units.

  • The acquisition is expected to close before the end of 2022, and a team of over 400 employees will join Catalent.

  • Mayne Pharma and Catalent have also agreed on a long-term supply agreement whereby the Greenville facility will continue manufacturing multiple Mayne Pharma products.

  • Catalent held cash & cash equivalents of $786 million at the end of the March quarter.

  • Price Action: CTLT shares closed at $108.13 on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.